1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. UCB Acquires IMIDomics

M&A Deal Summary

UCB Acquires IMIDomics

On March 4, 2024, UCB acquired life science company IMIDomics

Acquisition Highlights
  • This is UCB’s 7th transaction in the Life Science sector.
  • This is UCB’s 8th transaction in the United States.
  • This is UCB’s 2nd transaction in California.

M&A Deal Summary
Date 2024-03-04
Target IMIDomics
Sector Life Science
Buyer(s) UCB
Deal Type Add-on Acquisition

Target

IMIDomics

San Rafael, California, United States
IMIDomics is dedicated to the advancement of novel medicines for immune-mediated inflammatory diseases (IMIDs). IMIDomics was founded in 2015 and is based in San Rafael, California.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

UCB

Brussels, Belgium
Category Company
Founded 1928
Sector Life Science
Employees9,000
Revenue 6.2B EUR (2024)
DESCRIPTION

UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.

DEAL STATS #
Overall 11 of 11
Sector: Life Science M&A 7 of 7
Type: Add-on Acquisition M&A Deals 9 of 9
State: California M&A 2 of 2
Country: United States M&A 8 of 8
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-19 Zogenix

Emeryville, California, United States

Zogenix is a pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. Zogenix was founded in 2006 and is based in Emeryville, California.

Buy $1.9B
Mergr

Solution for

Product

Company

Legal